Effect of cytochrome p450 3a4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkins lymphoma

Clinical Pharmacokinetics

Volumn 50, Issue 12, 2011, Pages 781-791

  Hellmann, Andrzej ^a   Rule, Simon ^b   Walewski, Jan ^c   Shpilberg, Ofer ^d   Feng, Huaibao ^e   Van De Velde, Helgi ^f   Patel, Hamina ^g   Skee, Donna M ^e   Girgis, Suzette ^e   Louw, Vernon J ^h  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b DERRIFORD HOSPITAL   (United Kingdom)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d RABIN MEDICAL CENTER   (Israel)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^g JOHNSON AND JOHNSON   (United States)

^h UNIVERSITY OF THE FREE STATE   (South Africa)

Author keywords

Antineoplastics; Bortezomib; Dexamethasone; Drug interactions; Multiple myeloma; Non Hodgkins lymphoma; Pharmacokinetics; Pharmacology; Rifampicin

Indexed keywords

BORTEZOMIB; CYTOCHROME P450 3A4; DEXAMETHASONE; PROTEASOME; RIFAMPICIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAPHY; ENZYME INHIBITION; FATIGUE; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; OPEN STUDY; PARALLEL DESIGN; PHARMACODYNAMICS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; TREATMENT RESPONSE; VITAL SIGN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BORONIC ACIDS; CYTOCHROME P-450 CYP3A; DEXAMETHASONE; DRUG COMBINATIONS; ENZYME INDUCTION; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROTEASE INHIBITORS; PYRAZINES; RIFAMPIN;

EID: 81255195686     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11594410-000000000-00000     Document Type: Article

References (29)

1. Egger T, Dormann H, Ahne G, et al. Identification of adverse drug reactions in geriatric inpatients using a computerised drug database. Drugs Aging 2003; 20: 769-76 (Pubitemid 36995253)
2. Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther 2007; 32: 169-75 (Pubitemid 46449710)
3. McLeod HL. Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol 1998; 45: 539-44 (Pubitemid 28270908)
4. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-22 (Pubitemid 29269108)
5. de Vos S, Goy A, Dakhil SR, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol 2009; 27: 5023-30
6. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009; 113: 6069-76
7. Coiffier B, Osmanov E, Hong X, et al. A phase 3 trial comparing bortezomib plus rituximab with rituximab alone in patients with relapsed or refractory, rituximab-naive or-sensitive, follicular lymphoma [abstract]. 52nd Annual Meeting and Exposition, American Society of Hematology; 2010 Dec 4-7; Orlando (FL)
8. Uttamsingh V, Lu C, Miwa G, et al. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos 2005; 33: 1723-8 (Pubitemid 41539972)
9. Venkatakrishnan K, Rader M, Ramanathan RK, et al. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study. Clin Ther 2009; 31: 2444-58
10. Quinn DI, Nemunaitis J, Fuloria J, et al. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. Clin Pharmacokinet 2009; 48: 199-209
11. US FDA. Drug development and drug interactions: table of substrates, inhibitors and inducers [online]. Available from URL: http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/DrugInteractions Labeling/ucm093664.htm [Accessed 2011 Sep 27]
12. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM2005-01 phase III trial. J Clin Oncol 2010; 28: 4621-9
13. Kropff MH, Bisping G, Wenning D, et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 2005; 29: 587-90 (Pubitemid 40327248)
14. Minnema MC, van der Spek E, van de Donk NW, et al. New developments in the treatment of patients with multiple myeloma. Neth J Med 2010; 68: 24-32
15. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press, 1949: 199-205
16. National Cancer Institute. Common terminology criteria for adverse events v3.0 (CTCAE) [online]. Available from URL: http://ctep.cancer.gov/protocol Development/electronic-applications/docs/ctcaev3.pdf [Accessed 2011 Oct 3]
17. Lightcap ES, McCormack TA, Pien CS, et al. Proteasome inhibition measurements: clinical application. Clin Chem 2000; 46: 673-83 (Pubitemid 30318423)
18. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-23 (Pubitemid 28435189)
19. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
20. Huang SM, Temple R, Throckmorton DC, et al. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 2007; 81: 298-304 (Pubitemid 46174829)
21. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oralmidazolam.Clin Pharmacol Ther 1996; 59: 7-13 (Pubitemid 26046768)
22. Nassr N, Huennemeyer A, Herzog R, et al. Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects. Br J Clin Pharmacol 2009; 68: 580-7
23. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006; 91: 1498-505 (Pubitemid 44736116)
24. Delforge M, Blade J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010; 11: 1086-95
25. Phuphanich S, Supko JG, Carson KA, et al. Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol 2010; 100: 95-103
26. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsedmultiplemyeloma.NEngl JMed 2005; 352: 2487-98
27. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br JHaematol 2004; 127: 165-72 (Pubitemid 39371809)
28. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867-74 (Pubitemid 46655613)
29. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-17 (Pubitemid 36741588)